Aspirin treatment

Phase 3Small molecule

VVA Office of Research and Development

Aspirin treatment is one of 29 small molecule programs targeting Moyamoya disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Moyamoya DiseaseNot yet recruiting

AneurysmActive, not recruiting

Brain InfarctionActive, not recruiting

Moyamoya DiseasePreclinical

Not yet recruiting

AneurysmPreclinical

Active, not recruiting

Brain InfarctionPhase 3

Active, not recruiting

Competition

Competitive Landscape

30 competitors in Aneurysm

#DrugCompanyPhaseTrials

Plavix

Sanofi

Approved

2 2

Keppra

UCB

Approved

2 3

Tecfidera

Biogen

Approved

1 4

Aggrastat

MMedicure

Approved

2 5

Effient

CCosette Pharmaceuticals, Inc.

Approved

1 6

Pletal

Otsuka

Approved

1 7

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Approved

1 8

Xarelto

Coumadin

Remicade

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

ApprovedActive, not recruiting

Brain Infarction

NCT04698031

N/ARecruiting

Aneurysm

NCT07089862

Q1 2030

PreclinicalNot yet recruiting

Moyamoya Disease

NCT07762547

Clinical

Trials by Indication[1]

Aneurysm1 trial

INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT)

Recruiting·—·N/A·NCT07089862·2,500 enrolled

Moyamoya disease1 trial

Study on the Effects of Pharmacological and Physical Therapy in Delaying the Progression of Moyamoya Disease (Moyamoya Syndrome) : Randomized Controlled Study

Not yet recruiting·BBeijing Tiantan Hospital·Preclinical·NCT07762547·724 enrolled

Brain Infarction1 trial

Stroke and Coated-Platelets - A Translational Research Initiative

Active, not recruiting·VVA Office of Research and Development·Approved·NCT04698031·134 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Aspirin treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aspirin treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aspirin treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — VA Office of Research and Development company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VVA Office of Research and Development

Aspirin treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2030

Trials by Indication[1]

Aneurysm1 trial

Moyamoya disease1 trial

Brain Infarction1 trial

References

Drug Info

Quick Facts

Related News